IN2013CH01199A - - Google Patents

Download PDF

Info

Publication number
IN2013CH01199A
IN2013CH01199A IN1199CH2013A IN2013CH01199A IN 2013CH01199 A IN2013CH01199 A IN 2013CH01199A IN 1199CH2013 A IN1199CH2013 A IN 1199CH2013A IN 2013CH01199 A IN2013CH01199 A IN 2013CH01199A
Authority
IN
India
Prior art keywords
formula
compounds
useful
preparation
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/IN2013/000639 priority Critical patent/WO2014147636A1/fr
Priority to HK16105434.5A priority patent/HK1217483B/xx
Priority to JP2016504852A priority patent/JP6185650B2/ja
Priority to SG11201507763RA priority patent/SG11201507763RA/en
Priority to BR112015024060A priority patent/BR112015024060A2/pt
Priority to NZ712369A priority patent/NZ712369A/en
Priority to EA201591844A priority patent/EA029365B1/ru
Priority to DK13811624.9T priority patent/DK2976337T3/en
Priority to KR1020157030158A priority patent/KR101815307B1/ko
Priority to AU2013382944A priority patent/AU2013382944B2/en
Priority to CN201380074877.9A priority patent/CN105164119B/zh
Priority to ES13811624.9T priority patent/ES2674993T3/es
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Priority to EP13811624.9A priority patent/EP2976337B1/fr
Priority to US14/777,925 priority patent/US9790211B2/en
Priority to IN1199CH2013 priority patent/IN2013CH01199A/en
Priority to AP2015008742A priority patent/AP2015008742A0/xx
Priority to MX2015012350A priority patent/MX364929B/es
Priority to CA2907620A priority patent/CA2907620C/fr
Publication of IN2013CH01199A publication Critical patent/IN2013CH01199A/en
Priority to ZA2015/06804A priority patent/ZA201506804B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
IN1199CH2013 2013-03-20 2013-10-18 IN2013CH01199A (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CN201380074877.9A CN105164119B (zh) 2013-03-20 2013-10-18 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物
JP2016504852A JP6185650B2 (ja) 2013-03-20 2013-10-18 5−ht4受容体アゴニストとしての5−アミノ−キノリン−8−カルボキサミド誘導体
SG11201507763RA SG11201507763RA (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
BR112015024060A BR112015024060A2 (pt) 2013-03-20 2013-10-18 composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
NZ712369A NZ712369A (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
EA201591844A EA029365B1 (ru) 2013-03-20 2013-10-18 5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-htрецептора
DK13811624.9T DK2976337T3 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
KR1020157030158A KR101815307B1 (ko) 2013-03-20 2013-10-18 5-ht4 수용체 효능제로서 5-아미노-퀴놀린-8-카르복사미드 유도체
AU2013382944A AU2013382944B2 (en) 2013-03-20 2013-10-18 5-Amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
PCT/IN2013/000639 WO2014147636A1 (fr) 2013-03-20 2013-10-18 Dérivés 5-amino-quinoline-8-carboxamides en tant qu'agonistes du récepteur 5-ht4
HK16105434.5A HK1217483B (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
ES13811624.9T ES2674993T3 (es) 2013-03-20 2013-10-18 Derivados de 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-HT4
EP13811624.9A EP2976337B1 (fr) 2013-03-20 2013-10-18 Dérivés de 5-amino-quinoline-8-carboxamide en tant qu'agonistes du récepteur 5-ht4
US14/777,925 US9790211B2 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
IN1199CH2013 IN2013CH01199A (fr) 2013-03-20 2013-10-18
AP2015008742A AP2015008742A0 (en) 2013-03-20 2013-10-18 5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
MX2015012350A MX364929B (es) 2013-03-20 2013-10-18 Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.
CA2907620A CA2907620C (fr) 2013-03-20 2013-10-18 Derives 5-amino-quinoline-8-carboxamides en tant qu'agonistes du recepteur 5-ht4
ZA2015/06804A ZA201506804B (en) 2013-03-20 2015-09-14 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1199CH2013 IN2013CH01199A (fr) 2013-03-20 2013-10-18

Publications (1)

Publication Number Publication Date
IN2013CH01199A true IN2013CH01199A (fr) 2015-08-14

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1199CH2013 IN2013CH01199A (fr) 2013-03-20 2013-10-18

Country Status (18)

Country Link
US (1) US9790211B2 (fr)
EP (1) EP2976337B1 (fr)
JP (1) JP6185650B2 (fr)
KR (1) KR101815307B1 (fr)
CN (1) CN105164119B (fr)
AP (1) AP2015008742A0 (fr)
AU (1) AU2013382944B2 (fr)
BR (1) BR112015024060A2 (fr)
CA (1) CA2907620C (fr)
DK (1) DK2976337T3 (fr)
EA (1) EA029365B1 (fr)
ES (1) ES2674993T3 (fr)
IN (1) IN2013CH01199A (fr)
MX (1) MX364929B (fr)
NZ (1) NZ712369A (fr)
SG (1) SG11201507763RA (fr)
WO (1) WO2014147636A1 (fr)
ZA (1) ZA201506804B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406434B (zh) * 2015-02-13 2020-09-11 苏文生命科学有限公司 作为5-ht4受体激动剂的酰胺化合物
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708174A (en) 1992-03-12 1998-01-13 Smithkline Beecham P.L.C. Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
US5705498A (en) 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
WO2001095903A1 (fr) * 2000-06-15 2001-12-20 Respiratorius Ab Antagonistes du recepteur 5-ht3 destines au traitement de troubles englobant la constriction des voies aeriennes
JP4688799B2 (ja) * 2003-06-19 2011-05-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 5ht4−拮抗性4−(アミノメチル)−ピペリジンベンズアミド
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
WO2005061483A2 (fr) 2003-12-23 2005-07-07 Bio-Medisinsk Innovasjon As Modulateurs de recepteurs peripheriques 5-ht
WO2005092882A1 (fr) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
WO2007010390A1 (fr) 2005-07-22 2007-01-25 Pfizer Japan Inc. Derives d’ndazolecarboxamides en tant qu'agonistes des recepteurs 5ht4
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
CN107260736A (zh) 2010-02-12 2017-10-20 株式会社AskAt 用于治疗痴呆的5‑ht4受体激动剂
KR20120123089A (ko) 2010-02-16 2012-11-07 화이자 인코포레이티드 5-HT₄ 수용체의 부분 효능제인 (R)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조[d]이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2H-피란-4-올

Also Published As

Publication number Publication date
MX364929B (es) 2019-05-14
JP6185650B2 (ja) 2017-08-23
AU2013382944A1 (en) 2015-10-08
CN105164119B (zh) 2017-12-08
EP2976337B1 (fr) 2018-05-02
EP2976337A1 (fr) 2016-01-27
JP2016516089A (ja) 2016-06-02
US20160280694A1 (en) 2016-09-29
EA201591844A1 (ru) 2016-08-31
SG11201507763RA (en) 2015-10-29
CA2907620A1 (fr) 2014-09-25
NZ712369A (en) 2016-11-25
CA2907620C (fr) 2018-03-13
KR20160004274A (ko) 2016-01-12
DK2976337T3 (en) 2018-07-16
AP2015008742A0 (en) 2015-09-30
EA029365B1 (ru) 2018-03-30
ZA201506804B (en) 2016-07-27
ES2674993T3 (es) 2018-07-05
MX2015012350A (es) 2016-05-09
AU2013382944B2 (en) 2016-08-04
WO2014147636A8 (fr) 2014-12-04
HK1217483A1 (zh) 2017-01-13
WO2014147636A1 (fr) 2014-09-25
CN105164119A (zh) 2015-12-16
KR101815307B1 (ko) 2018-01-04
US9790211B2 (en) 2017-10-17
BR112015024060A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
IN2015DN01156A (fr)
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
WO2014155300A3 (fr) Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
PH12017500089B1 (en) Aldosterone synthase inhibitors
EA201600434A1 (ru) Применение производных бензимидазолпролина
MX368214B (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
MX2016008898A (es) Antagonistas selectivos de nr2b.
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
IN2013MU03862A (fr)
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
MX360001B (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
NZ712369A (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
PH12015502703A1 (en) Pharmaceutical compositions
IN2013MU03838A (fr)
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.